Introduction:
Thyroid cancer is the most prevalent cancer among endocrine malignancies. In clinically, surgical resection combined with radioactive iodine therapy has been proved effective in treating differentiated thyroid cancer, including papillary and follicular thyroid cancers (FTC). However, patients with incurable differentiated thyroid cancer (DTC), poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) exhibit worse prognosis. Therefore, a novel and effective treatment is urgently needed to deal with the current treatment.
Evodiamine is one of the important components isolated from Chinese herb Wu-Chu-Yu, and has been demonstrated to contribute on anti-inflammatory effects, anti-angiogenesis, anti-tumor growth, anti-invasive and metastatic activities, and up-regulating apoptosis.
In the present study, we examined the effects of evodiamine in FTC, PDTC and ATC cells, respectively. Evodiamine inhibited cellular proliferation and the colonies formation of FTC, PDTC and ATC cells. Cell cycle arrest at G2/M phase was found in all of the cells during evodiamine treatment. Moreover, caspase-dependent apoptosis in these cells was also revealed under evodiamine treatment. In addition, autophagy induction was also found in evodiamine treated human thyroid cancer cells. Finally, we verified the effects of evodiamine on anti-human thyroid cancers in a xenograft nude mice model. Our results demonstrate that evodiamine induces cell cycle arrest, caspase-dependent apoptosis and autophagy leading to inhibit proliferation of multiple types of human thyroid cancer cells. We suggest that evodiamine could be a chemo-therapeutic candidate for human thyroid cancers. Figure 6 . Evodiamine induced caspase-dependent apoptosis, and apoptosis occurred through an extrinsic and/or intrinsic pathway in human thyroid cancer cells. ARO cells and SW579 were incubated with evodiamine for 72 hrs and WRO cells were treated with evodiamine for 24 hrs and the expressions of caspase, Bid, Bcl-XL and PARP were detected by Western blotting. Z-VAD-FMK, a pan-caspase inhibitor, was used to block the activations of caspase mediated by evodiamine and GAPDH was used as a loading control. In the present study, we demonstrated that evodiamine could suppress human thyroid cancer cells proliferation. Cell cycle arrest, caspase-dependent apoptosis and autophagy were observed in human thyroid cancer cells during evodiamine treatment. Moreover, evodiamine was demonstrated to suppress the tumorigenesis in vitro and in vivo. Our findings elevate that evodiamine is a potential therapeutic agent against incurable human thyroid cancer and is worthy of further clinical investigation. Figure 8 . Evodiamine inhibited tumorigenesis of human thyroid cancer cells in a nude mice model. The mice were injected subcutaneously with ARO cells, and treated without or with evodiamine, the tumor weight were determined after 21 days treatment.
V. Evodiamine elevated caspasedependent apoptosis

Conclusions: II. Evodiamine inhibited colonies formation in ARO cells
III. Evodiamine induced G2/M arrest
VI. Evodiamine suppressed tumorigenesis of human thyroid cancer cells in a xenograft nude mice model
